NasdaqGM:PRTK

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. More Details


Snowflake Analysis

High growth potential and slightly overvalued.


Similar Companies

Share Price & News

How has Paratek Pharmaceuticals's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: PRTK's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.4%

PRTK

-4.8%

US Pharmaceuticals

-4.1%

US Market


1 Year Return

59.0%

PRTK

1.5%

US Pharmaceuticals

12.0%

US Market

Return vs Industry: PRTK exceeded the US Pharmaceuticals industry which returned 1.5% over the past year.

Return vs Market: PRTK exceeded the US Market which returned 12% over the past year.


Shareholder returns

PRTKIndustryMarket
7 Day-1.4%-4.8%-4.1%
30 Day-9.8%-5.0%-0.2%
90 Day11.7%-4.9%2.8%
1 Year59.0%59.0%4.1%1.5%14.6%12.0%
3 Year-78.2%-78.2%19.9%10.9%35.8%26.8%
5 Year-73.4%-73.4%30.7%15.6%75.2%55.6%

Price Volatility Vs. Market

How volatile is Paratek Pharmaceuticals's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Paratek Pharmaceuticals undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: PRTK ($4.88) is trading below our estimate of fair value ($120.22)

Significantly Below Fair Value: PRTK is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: PRTK is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: PRTK is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate PRTK's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: PRTK has negative assets, so we can't compare its PB Ratio to the US Pharmaceuticals industry average.


Next Steps

Future Growth

How is Paratek Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 5 analysts?

73.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PRTK is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: PRTK is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: PRTK's is expected to become profitable in the next 3 years.

Revenue vs Market: PRTK's revenue (35% per year) is forecast to grow faster than the US market (10% per year).

High Growth Revenue: PRTK's revenue (35% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if PRTK's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Paratek Pharmaceuticals performed over the past 5 years?

-10.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: PRTK is currently unprofitable.

Growing Profit Margin: PRTK is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PRTK is unprofitable, and losses have increased over the past 5 years at a rate of 10.9% per year.

Accelerating Growth: Unable to compare PRTK's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PRTK is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (18.7%).


Return on Equity

High ROE: PRTK's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Next Steps

Financial Health

How is Paratek Pharmaceuticals's financial position?


Financial Position Analysis

Short Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PRTK has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PRTK has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PRTK's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PRTK has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PRTK has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is Paratek Pharmaceuticals's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate PRTK's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PRTK's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PRTK's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PRTK's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of PRTK's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.4yrs

Average management tenure


CEO

Evan Loh (61 yo)

1.33yrs

Tenure

US$2,355,896

Compensation

Dr. Evan Loh, M.D., FACC, FAHA, has been the Chief Executive Officer of Paratek Pharmaceuticals, Inc. since June 25, 2019. Dr. Loh was the President at Paratek Pharmaceuticals, Inc. since June 2014 until J ...


CEO Compensation Analysis

Compensation vs Market: Evan's total compensation ($USD2.36M) is above average for companies of similar size in the US market ($USD1.36M).

Compensation vs Earnings: Evan's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Michael Bigham
Executive Chairman6yrsUS$2.33m1.19%
$ 2.6m
Evan Loh
CEO & Director1.33yrsUS$2.36m0.68%
$ 1.5m
Adam Woodrow
President & Chief Commercial Officer1.33yrsUS$1.40m0.34%
$ 748.7k
William Haskel
Senior VPno dataUS$1.25m0.30%
$ 670.7k
Sarah Higgins
VP, Controller and Interim Principal Financial & Accounting Officer1.5yrsno datano data
Jason Burdette
Senior Vice President of Technical Operations1.75yrsno datano data
Ben Strain
VP of of Investor Relations & Corporate Communications and Chief of Staff to the CEO2.58yrsno datano data
Christine Coyne
Vice President of Marketing2.75yrsno datano data
Karen McGrath
Senior Vice President of Human Resources1.25yrsno datano data
Randall Brenner
Chief Development & Regulatory Officer1.33yrsno data0.16%
$ 346.8k

1.4yrs

Average Tenure

55.5yo

Average Age

Experienced Management: PRTK's management team is not considered experienced ( 1.4 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Michael Bigham
Executive Chairman6yrsUS$2.33m1.19%
$ 2.6m
Evan Loh
CEO & Director1.33yrsUS$2.36m0.68%
$ 1.5m
Jeffrey Stein
Independent Director6yrsUS$142.78k0.022%
$ 49.4k
Thomas Dietz
Independent Outside Director6yrsUS$151.03k0.0099%
$ 21.9k
Kristine Peterson
Independent Outside Director4.58yrsUS$132.28k0.030%
$ 65.9k
Timothy Franson
Independent Outside Director5.25yrsUS$130.53k0.030%
$ 65.9k
Robert Radie
Independent Outside Director6yrsUS$136.03k0.015%
$ 32.9k
Rolf Hoffmann
Director2.5yrsUS$120.03k0.019%
$ 41.5k

6.0yrs

Average Tenure

61yo

Average Age

Experienced Board: PRTK's board of directors are considered experienced (6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 39.5%.


Top Shareholders

Company Information

Paratek Pharmaceuticals, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Paratek Pharmaceuticals, Inc.
  • Ticker: PRTK
  • Exchange: NasdaqGM
  • Founded: 1996
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$221.490m
  • Shares outstanding: 45.39m
  • Website: https://paratekpharma.com

Number of Employees


Location

  • Paratek Pharmaceuticals, Inc.
  • 75 Park Plaza
  • 4th Floor
  • Boston
  • Massachusetts
  • 2116
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PRTKNasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDOct 2014
N4CNDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2014

Biography

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health thre ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/10/30 03:23
End of Day Share Price2020/10/29 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.